Circio Holding ASA
Research Circio Holding ASA (CRNA) on Bullrun: market cap NOK 2.19B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCRNA
- ExchangeOL
- CountryNorway
- SectorHealthcare
- IndustryBiotechnology
- CurrencyNOK
- Market capNOK 2.19B
- Financial periodFY2025
- RevenueNOK 0
- Net income-NOK 45.91M
- Free cash flow-NOK 45.82M
Valuation Snapshot
latest market cap is NOK 2.19B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | NOK 0 | -NOK 45.91M | -NOK 45.82M | n/a | -0.43 | NOK 6.04M | NOK 8.37M | -NOK 12.49M |
| FY2024 | NOK 0 | NOK 57.52M | -NOK 40.72M | n/a | 2.7 | NOK 18.21M | NOK 17.36M | -NOK 12.51M |
| FY2023 | NOK 123.00K | -NOK 112.94M | -NOK 89.39M | n/a | -16.12 | NOK 21.90M | NOK 110.43M | -NOK 98.54M |
| FY2022 | NOK 10.00M | -NOK 432.90M | -NOK 113.80M | n/a | -2.23 | NOK 62.97M | NOK 63.42M | NOK 2.57M |
| FY2021 | NOK 0 | -NOK 97.97M | -NOK 85.40M | n/a | -1.1 | NOK 181.68M | NOK 57.07M | NOK 417.73M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | NOK 2.19B | n/a | n/a | n/a |
About Circio Holding ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a research collaboration with United Immunity Co., Ltd.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Circio Holding ASA's market cap?
Circio Holding ASA's market capitalization is NOK 2.19B.
What does Circio Holding ASA do?
Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a research collaboration with United Immunity Co., Ltd. for the development of vivo CAR-Macrophage (CAR-M) therapy; and Suzhou GenAssist Therapeutics Co., Ltd.